CSPCHA115

CSPCHA115 is a highly selective and potent small molecule antagonist of the chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2), also known as the prostaglandin D2 receptor 2 (DP2). It is being developed primarily for respiratory and allergic diseases such as asthma and allergic rhinitis. The drug has demonstrated rapid absorption, dose-proportional pharmacokinetics, and good tolerability in phase I clinical studies involving healthy subjects. The most common treatment-emergent adverse event observed was hypertriglyceridemia. No significant safety concerns have been identified to date. CSPCHA115 is being developed by CSPC ZhongQi Pharmaceutical Technology, a subsidiary of CSPC Pharmaceutical Group[1][2][3][4].